Michigan is currently home to 2237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Recruiting
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/07/2025
Locations: Clinical Site, Bloomfield Hills, Michigan
Conditions: Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Recruiting
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/07/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Light Chain (AL) Amyloidosis
No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair
Recruiting
The investigators hypothesize that not prescribing opioids after uncomplicated, outpatient IHR will be non-inferior to prescribing opioids (5 tablets of Oxycodone, 5mg; or surgeon preference for intolerance) with respect to requests for opioid refills. Additionally, the investigators believe there will be no significant difference in postoperative readmission for pain quality of life at 30 days in either group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Corewell Health, Royal Oak, Michigan
Conditions: Postoperative Pain, Inguinal Hernia
The Ailliance Post-Market Clinical Study
Recruiting
The purpose of this clinical study is to collect performance and safety data for post-market Medtronic devices indicated for cranial and/or spinal indication(s). Subjects are enrolled and followed postoperatively to 24 months. The Ailliance clinical study is intended to collect data congruous with routine clinical care practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Michigan Orthopaedic & Spine Surgeons, Rochester Hills, Michigan
Conditions: Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma, Spinal Tumor Case
Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)
Recruiting
The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEPĀ® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 80 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
07/07/2025
Locations: McLaren Center for Research and Innovation, Bay City, Michigan
Conditions: Carotid Stenosis, Carotid Artery Diseases
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Recruiting
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossove... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/07/2025
Locations: Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan
Conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
Recruiting
This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK121-NX administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK121-NX at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Solid Tumor
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Recruiting
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: University of Michigan Hospital, Ann Arbor, Michigan
Conditions: H3 K27M, Glioma
LowSalt4Life: A Mobile Application to Reduce Sodium Intake And Blood Pressure
Recruiting
This research is being done to learn if a smartphone app with and without a just in time adaptive intervention (JITAI) can help patients with hypertension manage their sodium intake and improve their blood pressure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: The University of Michigan, Ann Arbor, Michigan
Conditions: Hypertension, Blood Pressure
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Recruiting
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
Gender:
ALL
Ages:
Between 18 years and 123 years
Trial Updated:
07/07/2025
Locations: Research Site, Ann Arbor, Michigan
Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Recruiting
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic